>…Avastin is a smaller protein, thus potentially slightly more capable of crossing the retinal-blood barrier, but the chance of it getting into the bloodstream in sufficient quantity to do harm elsewhere is almost nil, in my humble opinion.<
Lucentis is smaller: about one-third the size of Avastin.
>raises the question of why Avastin is so much cheaper to produce on the scale needed to treat AMD…<
Gram for gram, Lucentis is cheaper to produce than Avastin because it is made using E. coli.
>why [Avastin] couldn't be packaged in smaller single use vials for AMD thus eliminating the "compounding" issues.<
If DNA did that, then they would be legally liable for any problems. The FDA might also question why DNA wanted to make a dose suitable only for an off-label use!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
